Literature DB >> 1773355

GM1 ganglioside treatment reduces visual deficits after graded crush of the rat optic nerve.

J Sautter1, M Schwartz, R Duvdevani, B A Sabel.   

Abstract

Despite numerous reports of beneficial effects of GM1 ganglioside treatment following brain lesions in animals, the underlying neurobiological mechanism of ganglioside-induced functional restoration is still unclear. In order to obtain a better insight into this question, we have made use of a newly developed animal model of brain injury that would potentially permit us to determine the causal relationship(s) among behavioral and neuroanatomical/neurochemical parameters of restoration of function. Following graded crush of the adult rat optic nerve, we have treated the rats with intraperitoneally injected gangliosides and studied the functional outcome with electrophysiological and behavioral parameters. The electrophysiological recording of the compound action potential (CAP) from excised rat optic nerve revealed a significant loss of CAP throughout the first 2 weeks after the injury. However, when rats were treated daily for 7 days with GM1-gangliosides, the CAP measured 10 days after the crush was significantly larger compared to operated controls without treatment. Thus, GM1 appeared to be capable of delaying or partially preventing retinal ganglion cells or their axons from secondary degeneration. Loss of visual function was also evident on the behavioral level of analysis: when rats with unilateral optic nerve crush were evaluated in a visual orienting paradigm, the rats revealed deficits in their ability to orient towards small, moving visual stimuli. However, within about 2 weeks, the animals recovered spontaneously to near normal performance. Daily treatment with GM1-gangliosides was found to significantly improve outcome, largely due to a reduction of the immediate post-lesion deficit. In a second behavioral experiment we also created graded crush in rats bilaterally and evaluated the animals visual capacities in a two-choice brightness discrimination task. In this task, an initial loss of function was followed by recovery within about 2 weeks, but GM1 treatment was without beneficial effects in this paradigm. It is concluded that GM1 improves outcome after graded crush of the adult rat optic nerve, although it appears that improved function needs to be documented with sufficiently sensitive behavioral assays.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1773355     DOI: 10.1016/0006-8993(91)91732-g

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Gangliosides and neurological diseases.

Authors:  P O Behan; B A Haniffah
Journal:  BMJ       Date:  1992-11-28

2.  Toxicity of polymeric nanoparticles in vivo and in vitro.

Authors:  Nadine Voigt; Petra Henrich-Noack; Sarah Kockentiedt; Werner Hintz; Jürgen Tomas; Bernhard A Sabel
Journal:  J Nanopart Res       Date:  2014-05-06       Impact factor: 2.253

3.  Neurosteroid allopregnanolone reduces ipsilateral visual cortex potentiation following unilateral optic nerve injury.

Authors:  Elena G Sergeeva; Claudia Espinosa-Garcia; Fahim Atif; Machelle T Pardue; Donald G Stein
Journal:  Exp Neurol       Date:  2018-05-02       Impact factor: 5.330

4.  A behavioral model of excitotoxicity: retinal degeneration, loss of vision, and subsequent recovery after intraocular NMDA administration in adult rats.

Authors:  B A Sabel; J Sautter; T Stoehr; R Siliprandi
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

5.  Optic nerve inflammation and demyelination in a rodent model of nonarteritic anterior ischemic optic neuropathy.

Authors:  Bernard J Slater; Fernandino L Vilson; Yan Guo; Daniel Weinreich; Shelly Hwang; Steven L Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-05       Impact factor: 4.799

6.  Cholinergic Potentiation of Restoration of Visual Function after Optic Nerve Damage in Rats.

Authors:  Mira Chamoun; Elena G Sergeeva; Petra Henrich-Noack; Shaobo Jia; Lisa Grigartzik; Jing Ma; Qing You; Frédéric Huppé-Gourgues; Bernhard A Sabel; Elvire Vaucher
Journal:  Neural Plast       Date:  2017-08-27       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.